Podcasts

Episode 22 | Accelerating Progress in Oncogene-driven Lung Cancer

Dr Deme Karikios, Dr Wanda Cui and A/Prof Chris Karapetis discuss the advances in oncogene-driven lung cancer and what this means for trial design, patients and treatment practices in Australia.

Accelerating Progress in Oncogene-driven Lung Cancer

Episode Summary

Join us for the latest TOGA podcast about Accelerating Progress in Oncogene-driven Lung Cancer. Dr Deme Karikios, Dr Wanda Cui and A/Prof Chris Karapetis discuss the advances in oncogene-driven lung cancer and what this means for trial design, patients and treatment practices in Australia. We examine the survival data for the common and not so common mutated lung cancers, as well as the future view.

Show Hosts

This episode’s host are:

  • Dr Deme Karikios, Medical Oncologist and Director of Clinical Trials, Nepean Cancer Centre
  • Dr Wanda Cui, Medical Oncologist, Peter MacCallum Cancer Centre
  • A/Prof Chris Karapetis, Head of the Department of Medical Oncology and Director of Clinical Research, Flinders Medical Centre

Play Episode 22 | Accelerating Progress in Oncogene-driven Lung Cancer

More Podcasts

A conversation with Associate Professor Tom John and Professor Ben Solomon where they discuss the increased survival benefits for patients with oncogene driven lung cancer
In this Podcast, Mark Scott talks with Alexandra Golledge about her challenges in diagnosis, searching for the best treatments available, living in a regional area
Prof Nick Pavlakis and Prof Emily Stone join discuss the remarkable advances in screening, diagnosing and treating lung cancer that occurred during 2020.
Dorothy Keefe, CEO of Cancer Australia and Mark Scott discuss the COVID impact on diagnosing and treating lung cancer patients.
A fireside chat with Prunella Blinman, Shankar Siva and our three Preceptees: Anna Lawless, Abhijit Pal and Melanie Rabbets about their experiences, their learnings, what
In this episode, Prof Anna Nowak and A/Prof Steven Kao discuss the emerging treatments for mesothelioma patients and the DREAM3R trial.